Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30136351 | 0.84 | LPL (0.38) | CA1CA2CA9LPLLIPG | |
| SCHEMBL31256282 | 0.82 | LPL (0.32) | CA1CA2CA9LPLLIPG | |
| SCHEMBL25533300 | 0.79 | — | — | |
| SCHEMBL14956259 | 0.76 | LPL (0.40) | CA1CA2CA9LPLLIPG | |
| SCHEMBL14956695 | 0.76 | LPL (0.41) | CA1CA2CA9LPLLIPG | |
| SCHEMBL31618649 | 0.75 | LPL (0.35) | CA1CA2CA9LPLLIPG | |
| SCHEMBL23043819 | 0.74 | LPL (0.36) | CA1CA2CA9LPLLIPG | |
| SCHEMBL16722762 | 0.74 | LPL (0.41) | CA1CA2CA9LPLLIPG | |
| SCHEMBL1660361 | 0.72 | LPL (0.40) | CA1CA2CA9LPLLIPG | |
| SCHEMBL24616359 | 0.72 | LPL (0.35) | CA1CA2CA9LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4713330-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| WO-2025217420-A1 | PYRIDINONE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4592296-A1 | NOVEL TETRAHETEROCYCLE COMPOUND | Idience Co., Ltd. (KR) | 2025-07-30 | — | — | EP | disclosed |
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | BIOMEA FUSION, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2022262686-A1 | KRAS G12D INHIBITORS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022262838-A1 | DEUTERATED COMPOUNDS USEFUL AS KRAS G12D INHIBITORS | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022237649-A1 | EXOCYCLIC AMINO QUINAZOLINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CA1 2449/4885CA2 730/4885CA9 1058/4885 |
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | KRAS, NRAS, TP53 | CA1 2748/4885CA2 2881/4885CA9 2085/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | CA1 2780/4885CA2 1408/4885CA9 566/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CA1 2721/4885CA2 1272/4885CA9 1157/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | CA1 3753/4885CA2 3417/4885CA9 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.